Cytokinetics CYTK Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromConvertibleDebt.
The official record: Cytokinetics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's debt issuance proceeds?
- Cytokinetics (CYTK) reported debt issuance proceeds of $182.37M in Q4 2025.
- What is the long-term trend for Cytokinetics's debt issuance proceeds?
- Over 3 years (2022 to 2025), Cytokinetics's debt issuance proceeds has grown at a 11.7% compound annual growth rate (CAGR), from $523.59M to $729.46M.
- What does debt issuance proceeds mean?
- Cash received from taking on new debt.
- How do you interpret debt issuance proceeds?
- Higher inflows indicate successful access to credit markets to fund operations, while lower inflows suggest limited borrowing capacity or a preference for equity financing.
- How does debt issuance proceeds compare across companies?
- Varies significantly based on the company's credit rating and the prevailing interest rate environment.